Spot the right biotech at the right time, and fortunes can be made.
Look at Greenwich Lifesciences (GLSI) for example. Between Dec. 8 and today, the stock exploded from $5.20 to $86.29. All after a mid-stage study showed that 100% of patients were still alive at a median of five years after receiving the company’s drug, GP2.
“Five years is considered the gold standard in follow-up time period for recurrence in breast cancer patients,” according to Investor’s Business Daily. The biotech company administered GP2 after patients underwent surgery and then received Roche’s breast cancer treatment, Herceptin. Greenwich is now preparing to begin a Phase 3 study in 2021.”
Or look at Fate Therapeutics (FATE).
The stock just ran from $60.80 to $95 after posting positive interim data from its Phase 1 study of FT516 in combination with rituximab for patients with relapsed / refractory B-cell lymphoma.
“We are highly encouraged by these Phase 1 data, which clearly demonstrate that off-the-shelf, iPSC-derived NK cells can drive complete responses for cancer patients and that our proprietary hnCD16 Fc receptor can effectively synergize with and enhance the mechanism of action of tumor-targeted antibodies,” said Scott Wolchko, President and CEO of Fate Therapeutics.
“Importantly, the safety profile of FT516 continues to suggest multiple doses of iPSC-derived NK cells can be administered in the outpatient setting, and supports potential use across multiple lines of therapy, including as part of early-line CD20-targeted monoclonal antibody regimens, for the treatment of B-cell lymphoma.”
Longer-term, there’s plenty of opportunity, too.
In fact, by 2025, the sector could explode to a value of $727.1 billion, says Grand View Research thanks to sizable near-term catalysts.
For one, the sector is still one of the safest, most recession-proof investment around. After all, we can’t stop folks from aging, or from needing treatments for a large range of medical issues.
Two, an aging population is demanding more treatments in an effort to live longer lives. At the moment, there are 65 million people over the age of 70 in the United States. As this number continues to grow, we’ll see a need for more medication and treatment options.
There’s also incredible new innovation in genetics and technology, creating new life-saving and life enhancing opportunities. And three, big pharmaceutical companies are buying hot biotech companies to keep their pipelines full to avoid revenue shortfalls created by patent expirations.
The post Top Biotech Stocks That Could See More Upside appeared first on Morningology.
